A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in India
← catalyst calendarNCT07685769 · readout in 510 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 4
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
60estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-17 | estimated | When the study began enrolling |
| Primary completion | 2028-01-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-01-11 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Acute Treatment of Migraine
Intervention
- Drug: Rimegepant 75 mg ODT
Primary outcomes
what the primary-completion date above is the date OFIncidence of Treatment-emergent adverse events (TEAEs)
measured Up to 28 days
Incidence of Serious adverse events (SAEs)
measured up to 28 days
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed